DCEP regimen: Difference between revisions

	WikiDoc Resources for DCEP regimen
Articles
Most recent articles on DCEP regimen Most cited articles on DCEP regimen Review articles on DCEP regimen Articles on DCEP regimen in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on DCEP regimen Images of DCEP regimen Photos of DCEP regimen Podcasts & MP3s on DCEP regimen Videos on DCEP regimen
Evidence Based Medicine
Cochrane Collaboration on DCEP regimen Bandolier on DCEP regimen TRIP on DCEP regimen
Clinical Trials
Ongoing Trials on DCEP regimen at Clinical Trials.gov Trial results on DCEP regimen Clinical Trials on DCEP regimen at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on DCEP regimen NICE Guidance on DCEP regimen NHS PRODIGY Guidance FDA on DCEP regimen CDC on DCEP regimen
Books
Books on DCEP regimen
News
DCEP regimen in the news Be alerted to news on DCEP regimen News trends on DCEP regimen
Commentary
Blogs on DCEP regimen
Definitions
Definitions of DCEP regimen
Patient Resources / Community
Patient resources on DCEP regimen Discussion groups on DCEP regimen Patient Handouts on DCEP regimen Directions to Hospitals Treating DCEP regimen Risk calculators and risk factors for DCEP regimen
Healthcare Provider Resources
Symptoms of DCEP regimen Causes & Risk Factors for DCEP regimen Diagnostic studies for DCEP regimen Treatment of DCEP regimen
Continuing Medical Education (CME)
CME Programs on DCEP regimen
International
DCEP regimen en Espanol DCEP regimen en Francais
Business
DCEP regimen in the Marketplace Patents on DCEP regimen
Experimental / Informatics
List of terms related to DCEP regimen

← Older edit

VisualWikitext

Latest revision as of 17:40, 12 March 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]

Overview

DCEP regimen refers to a regimen consisting of Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients.^[1]

Regimen

DDexamethasone

CCyclophosphamide

EEtoposide

PCisplatin

Indications

Relapsed or refractory multiple myeloma^[1]

References

↑ ^1.0 ^1.1 Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K; et al. (2007). "Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients". J BUON. 12 (1): 41–4. PMID 17436400.

[pmid17436400-1] 1.0 ^1.1 Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K; et al. (2007). "Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients". J BUON. 12 (1): 41–4. PMID 17436400.

[1]

@@ Line 1: / Line 1: @@
 __NOTOC__
 {{SI}} {{CMG}}; {{AE}} {{AV}}
-{{SK}}
 ==Overview==
 {{PAGENAME}} refers to a regimen consisting of [[Dexamethasone]], [[cyclophosphamide]], [[etoposide]] and [[cisplatin]] (DCEP) for relapsed or refractory [[multiple myeloma]] patients.<ref name="pmid17436400">{{cite journal| author=Dadacaridou M, Papanicolaou X, Maltesas D, Megalakaki C, Patos P, Panteli K et al.| title=Dexamethasone, cyclophosphamide, etoposide and cisplatin (DCEP) for relapsed or refractory multiple myeloma patients. | journal=J BUON | year= 2007 | volume= 12 | issue= 1 | pages= 41-4 | pmid=17436400 | doi= | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17436400 }} </ref>
 ==Regimen==